SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca (LSE/STO/Nasdaq: AZN).
SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies.
“We have chosen to partner with SAGA because of the ultrasensitive performance of the SAGAsafe® technology and possibility to custom tailor highly complex dPCR assays to meet our desired analytical standards. We are excited about exploring this new area together with SAGA,” said James Hadfield, Director Epigenomics, Oncology Translational Medicine, Oncology R&D, AstraZeneca
SAGAsafe® is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods and can be used to quantify sequence variants in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!